VAXIMM AG, the Swiss-German biotechnology company, has appointed Matthias Schroff as its new chief executive officer. Dr Schroff was previously chief executive of Mologen AG where he built the company from an early preclinical enterprise to one with clinical-stage oncology programmes. Dr Schroff received his PhD in biochemistry from the Freie Universität Berlin at the Institute of Molecular Biology and Biochemistry where he was involved in clinical trials in immunotherapy from as early as 1994.
VAXIMM announced the appointment on 1 September 2016.
Copyright 2016 Evernow Publishing Ltd